The Filing Desk

Tango Therapeutics vs Viridian Therapeutics

Tango Therapeutics TNGX · Viridian Therapeutics VRDN · Pharmaceuticals

Viridian Therapeutics reported revenue of $71 million in fiscal 2025, about the same as Tango Therapeutics' $62 million in fiscal 2025. Tango Therapeutics' revenue grew 48.3% in its latest year, and Viridian Therapeutics' grew 23359.9%. Tango Therapeutics had an operating margin of -178.4%, against -512.9% at Viridian Therapeutics. Free cash flow was −$140 million at Tango Therapeutics and −$277 million at Viridian Therapeutics.

Side by side

Tango TherapeuticsViridian Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$62M$71M
Revenue growth48.3%23,359.9%
Revenue growth a year, last 5 years52.0%130.0%
Gross margin——
Operating margin−178.4%−512.9%
Net margin−162.8%−483.6%
Free cash flow−$140M−$277M
Free cash flow margin−224.3%−390.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count6.3%—
Last close$25.50$30.87
P/E at the last close——
Insider trades, last 12 monthssold $7.2 millionbought $20.0 million, sold $418,990
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Tango TherapeuticsViridian Therapeutics
Operating margin
Percent of revenue
Tango TherapeuticsViridian Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Tango TherapeuticsViridian Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Tango Therapeutics and Viridian Therapeutics pages.